Gene Expression Profiling and Association Studies Implicate the Neuregulin Signaling Pathway in Behçet's Disease Susceptibility by Xavier, J et al.
ORIGINAL ARTICLE
Gene expression profiling and association studies
implicate the neuregulin signaling pathway
in Behçet's disease susceptibility
Joana M. Xavier & Tiago Krug & Fereydoun Davatchi & Farhad Shahram &
Benedita V. Fonseca & Gorete Jesus & Filipe Barcelos & Joana Vedes &
Manuel Salgado & Bahar Sadeghi Abdollahi & Abdolhadi Nadji &
Maria Francisca Moraes-Fontes & Niloofar Mojarad Shafiee &
Fahmida Ghaderibarmi & José Vaz Patto & Jorge Crespo &
Sofia A. Oliveira
Received: 10 December 2012 /Revised: 1 February 2013 /Accepted: 7 March 2013 /Published online: 27 April 2013
# Springer-Verlag Berlin Heidelberg 2013
Abstract Behçet's disease (BD) is a complex disease with
genetic and environmental risk factors implicated in its etiol-
ogy; however, its pathophysiology is poorly understood. To
decipher BD's genetic underpinnings, we combined gene
expression profiling with pathway analysis and association
studies. We compared the gene expression profiles in periph-
eral blood mononuclear cells (PBMCs) of 15 patients and 14
matched controls using Affymetrix microarrays and found
that the neuregulin signaling pathway was over-represented
among the differentially expressed genes. The Epiregulin
(EREG), Amphiregulin (AREG), and Neuregulin-1 (NRG1)
genes of this pathway stand out as they are also among the top
differentially expressed genes. Twelve haplotype tagging
SNPs at the EREG-AREG locus and 15 SNPs in NRG1 found
associated in at least one published BD genome-wide associ-
ation study were tested for association with BD in a dataset of
976 Iranian patients and 839 controls. We found a novel
association with BD for the rs6845297 SNP located down-
stream of EREG, and replicated three associations at NRG1
(rs4489285, rs383632, and rs1462891). Multifactor dimen-
sionality reduction analysis indicated the existence of epistatic
interactions between EREG andNRG1 variants. EREG-AREG
andNRG1, which are members of the epidermal growth factor
(EGF) family, seem to modulate BD susceptibility through
main effects and gene–gene interactions. These association
findings support a role for the EGF/ErbB signaling pathway in
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BD pathogenesis that warrants further investigation and
highlight the importance of combining genetic and genomic
approaches to dissect the genetic architecture of complex
diseases.
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Introduction
Behçet's disease (BD) is a systemic immuno-inflammatory
disease characterized by the peculiar form it affects the organ-
ism, especially in the mucocutaneous and ocular structures. Its
most common clinical manifestations are recurrent orogenital
ulcerations and inflammatory eye lesions. Although its
etiopathogenesis remains to be elucidated, genetic (e.g., HLA-
B51) and environmental factors as well as immune-mediated
mechanisms have been pointed out as important factors [1].
Genome-wide association studies (GWAS) for BD re-
cently revealed two novel susceptibility loci at a genome-
wide significant level: IL23R-IL12RB2 and IL10 [2, 3].
However, the genetic susceptibility to BD is governed by
additional genes that cannot be pinpointed using this ap-
proach. To identify additional genetic risk factors for BD,
we hereby pursued another strategy which intersects data
from a genome-wide expression study with an in silico
pathway analysis and association studies.
Gene expression profiling allows the simultaneous monitor-
ing of the transcriptional behavior of thousands of genes, and
genes differentially expressed between patients and controls in
a relevant tissue are likely to be involved at some stage of the
pathogenic process. Gene profiling experiments have allowed
the identification of novel and unsuspected pathways involved
in disease etiology, including in rheumatic and immune dis-
eases [4–6]. Pathway analysis of differentially expressed genes
is a useful approach to highlight undetected patterns in the data
and to determine which differentially expressed genes to
follow-up in independent assays such as association studies.
This convergence of genomic and genetic approaches enables
data mining beyond the top findings. With this strategy, we
were able to highlight the role of the neuregulin signaling
pathway in BD pathogenesis and strengthen the previously
observed association of variants in NRG1 with BD.
Materials and methods
Gene profiling study subjects
Fourteen BD patients and 15 healthy controls were enrolled in
the gene expression study through the Hospital Infante D.
Pedro, Hospital de Sousa Martins, Hospital Pediátrico de
Coimbra and Instituto Português de Reumatologia in Portugal.
These participants are of Portuguese Caucasian origin. All
patients satisfied the International Criteria for Behçet's disease
(ICBD) [7]. Patients were considered immunosuppressed if
medicated with azathioprine, cyclosporine, deflazacort, or tha-
lidomide. BD patients with age-at-diagnosis after 60 years
were excluded. Controls were evaluated using the same eval-
uation procedures as the cases and selected when negative for
BD and any other rheumatologic or autoimmune disorder. This
research was approved by the ethics committee at Hospital
Infante D. Pedro and Instituto Português de Reumatologia
where the samples were collected. All participants were in-
formed of the study and provided informed written consent.
Total RNA isolation and microarray hybridization
Whole blood samples were obtained by venipuncture and
collected in BD Vacutainer CPT tubes (BD, Franklin Lakes,
NJ, USA). These samples were centrifuged to isolate
PBMCs, which were then washed twice. Total RNA was
extracted from PBMCs using RNeasy Mini kit (Qiagen,
Hilden, Germany) according to the protocol recommended
by the manufacturer. Total RNA (3.5 μg) from each indi-
vidual was hybridized to GeneChip Human Genome U133
Plus 2.0 microarrays (Affymetrix, Santa Clara, CA, USA) at
the Instituto Gulbenkian de Ciência's Affymetrix Core Fa-
cility following manufacturer's protocols. Extensive quality
control checks were performed in all steps of the process.
Gene expression data normalization and statistical analysis
The intensity array data were analyzed with their respective
CDF file from Affymetrix on the Partek software (Partek
Incorporated, St Louis, MO, USA). Background correction,
normalization, and summarization of the CEL files were
performed using the robust multichip average algorithm.
Differentially expressed genes among cases and controls
were identified with analysis of variance (ANOVA),
adjusting for known experimental (immunosuppression sta-
tus) and study design (geographic origin and scan date) co-
variates. The genes with more than 1.20-fold-change and
P≤0.05 were considered differentially expressed. To ac-
count for multiple testing, we calculated false discovery
rates (FDR) using the Partek Q value method [8].
The gene expression profiling was conducted and
reported in accordance with the minimum information about
microarray experiment (MIAME) guidelines [9]. The micro-
array data were deposited on Gene Expression Omnibus
(GEO) database (http://www.ncbi.nlm.nih.gov/projects/
geo/) with the accession number GSE17114.
Hierarchical clustering (HC) analysis was performed
using the Partek software. The effects of the geographic
origin of the participants, the scan date of the microarrays
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and the immunosuppression status of the participants were
removed using the batch-remove tool implemented in Partek
prior to visualization, since these visualization tools cannot
correct for study design batch effects.
Quantitative real-time polymerase chain reaction confir-
mation of some of the microarray results was not performed
because of an insufficient amount of RNA available for
several of the controls and patients used in this study.
Pathway analyses
Ingenuity Pathway Analysis 9.0 (IPA; Ingenuity Systems,
http://www.ingenuity.com) was used to functionally annotate
genes according to molecular networks, biological function,
and canonical pathways. An IPA list is built upon a very large
manually curated and up-to-date database of genes, proteins,
functions, interactions/networks, and pathways. Functional
analysis was performed on the 621 probe IDs differentially
expressed (P≤0.05 and absolute fold-change>1.20). The IPA
“Core Analysis” was run using the Human Genome U133
Plus 2.0 array as the reference set, using direct and indirect
relationships for network analysis, including endogenous
chemicals, data from Human species only, experimental ob-
served confidence, and all tissues, cell lines, and data sources.
The significance (P values) of the association between a
dataset and a canonical pathway was determined by compar-
ing the number of genes in a dataset that participate in a given
pathway to the total number of occurrences of these genes in
all pathway annotations. A Fisher's exact test was used to
calculate the P value to determine the probability that the
association between the genes in the dataset and the canonical
pathway is explained only by chance. The level of statistical
significance was set to P≤0.05.
Association study subjects
Patients (976) and 839 controls, ascertained and collected as
described previously [10], were included in the association
study. Diagnosis of BD was made according to the ICBD
criteria [7]. This research was approved by the ethics com-
mittee at the Tehran University for Medical Sciences, Iran.
All participants were informed of the study and provided
informed written consent.
Genotyping
Thirteen haplotype tagging SNPs (htSNP) at the EREG-
AREG locus (chr. 4: 75449724–75545341 bp) were identi-
fied in Haploview 4.1 [11] using genotypes of 30 European
(CEU) trios downloaded from the HapMap Release
24/phase II Nov08 (NCBI B36 assembly, dbSNP b126),
and with the following options: pairwise mode, r2>0.80,
and minor allele frequency (MAF)>0.1. Fifteen SNPs with
a r2<0.8 in NRG1 (chr. 8: 31517663–32066776 bp) found
associated with BD in either one of two published GWAS
(personal communications by Dr. Elaine Remmers and Dr.
Nobuhisa Mizuki) were genotyped.
Genomic DNA was extracted from whole blood samples
using a salting out procedure. SNPs were genotyped using
Sequenom's (San Diego, USA) iPlex assay (primer exten-
sion of multiplex products with detection by matrix assisted
laser desorption/ionization time-of-flight mass spectrome-
try) following the manufacturer's protocol and detected in
a Sequenom MassArray K2 platform. The primer sequences
are available in Supplementary Table 1 and were designed
using Sequenom's MassARRAY ® Assay Design 3.0 soft-
ware. The genotyping was performed at the Instituto
Gulbenkian de Ciência's Genomics Unit.
Extensive quality control was performed using eight
HapMap (http://hapmap.ncbi.nlm.nih.gov/) controls of diverse
ethnic affiliation, sample duplication within and across plates,
Mendelian inheritance check in three large pedigrees, Hardy–
Weinberg equilibrium (HWE) in the control group (P>0.01),
and a minimum of 95 % call rate for each SNP. Genotype
determinations were performed blinded to affection status.
Association analyses
Student's unpaired t tests and chi-square tests were used to
compare quantitative and qualitative clinical and demographic
data, respectively, between BD cases and controls. χ2 tests for
HWE in controls and crude allelic association of SNPs with
BD risk were performed using Haploview 4.1. The SNPassoc
v.1.4-9 package [12] implemented in the R freeware (http://
cran.r-project.org/) was used to assess the associations with
BD adjusted for gender. Odds ratios (ORs) and their associated
95 % confidence intervals (CIs) were calculated for SNPs with
significant allelic associations with BD. Results were consid-
ered significant below the conventional level of 0.05.
Meta-analyses
GWAS data for EREG-AREG and NRG1 SNPs (e.g., allele
counts, OR, CI) was obtained by personal communications
from Drs. Ahmet Gul and Elaine F. Remmers for the Turkish
dataset [2], and from Drs. Shigeaki Ohno, Nobuhisa Mizuki
and Akira Meguro for the Japanese dataset [3]. Fixed effects
(Mantel-Haenszel) meta-analyses were performed using the
rmeta package in R.2.7.2 and PLINK v1.047.
Gene–gene interactions
Epistasis between EREG-AREG and NRG1 variants was
detected and characterized using the multifactor dimensionality
reduction (MDR) method (v2.0 beta 8.3) (www.epistasis.org)
[13]. Missing genotypes were first imputed for each SNP using
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the PLINK database (http://pngu.mgh.harvard.edu/purcell/
plink/) [14] with genotypes from individuals in the CEU
HapMap population as a reference. MDR reduces high-
dimensional data into a single dimension data by pooling
multilocus genotypes into “high- risk” and “low-risk” groups
according to ratio of affected and unaffected individuals within
each genotype combination. This new multilocus variable is
then tested for its ability to predict disease status. Cross valida-
tion and testing balance accuracy (TBA) are used to select the
best models [13, 15]. The statistical significances of the best
models were calculated after 1,000 permutations using the
MDR Permutation Tool (v1.0, beta 2). Entropy-based interac-
tion dendrograms were drawn to interpret epistasis models.
Results
Gene expression study
The principal clinical and demographic characteristics of the
29 individuals used in the gene profiling study are shown in
Table 1. Cases and controls were matched for age-at-
examination (AEE) (mean AAE±SD of 37.1±11.0 years
in cases and 36.7±13.5 years in controls, P=9.39E-01).
All of the microarrays performed were of good quality
(average±SD of present calls and of background were 45.
0±3.0 % and 42.0±6.1 %, respectively).
Using analysis of variance on the normalized expression
data, 621 probe sets representing 508 genes (Supplementary
Table 2) were found differentially expressed among BD cases
and controls with a threshold of 1.20-fold-change, and P≤0.
05. 373 of these probe sets (representing 314 genes) were
down-regulated. All the probe sets with P≤0.05 also had a Q
value≤0.05. The false discovery rate was determined based on
Q values, as these have a higher apparent power when com-
pared to other standard methods [8]. The hierarchical cluster
diagram shows a distinct gene expression profile between
patients and controls that clearly separates the two groups of
samples (Fig. 1). The top 30 genes with larger fold-change
differences between cases and controls are shown in Table 2.
EREG, S100B (S100 calcium binding protein B), NAMPT
(nicotinamide phosphoribosyltransferase), AREG, and NRG1
were the top five genes under-expressed in patients, and
HBG1/HBG2 (hemoglobin subunit gamma-1/gamma-2),
SRSF6 (serine/arginine-rich splicing factor 6), LGALS2 (lec-
tin, galactoside-binding, soluble, 2), NEBL (nebulette), and
TRD@ (Tcell receptor delta locus) the top five over-expressed
genes in BD patients.
Pathway analysis
Pathway analysis of the differentially expressed genes was
performed using the Ingenuity Pathway Analysis (IPA).
This software enables the discovery and analyses of func-
tional relationships between differentially expressed genes
and gives information about the molecular networks, bio-
logical functions, and canonical pathways over-represented
among those genes.
Fourteen canonical pathways (Supplementary Table 3)
were found to be significantly over-represented among the
differentially expressed genes, including the lipid antigen
presentation by CD1 (4/22 genes, P=4.34E-04) and antigen
presentation (4/40 genes, P=9.12E-03) pathways which
have functions related to cell-mediated immunity. IPA anal-
ysis also highlighted several pathways related to cell signal-
ing such as the RhoA signaling (9/22 genes, P=1.72E-03),
Cdc42 signaling (9/143 genes, P=3.51E-03), JAK2 in
hormone-like cytokine signaling (4/34 genes, P=8.17E-03),
caveolar-mediated endocytosis signaling (6/81 genes, P=8.
88E-03), and neuregulin signaling (6/95 genes, P=2.04E-
02). Interestingly, three genes of the neuregulin signaling
pathway—EREG (−2.39 fold-change, P=2.99E-02), AREG
(−1.80-fold-change, P=4.90E-02), and NRG1 (−1.76-fold-
change, P=3.12E-02)—were among the most differentially
expressed genes between cases and controls, and therefore
these three genes were selected for follow up in an association
study.
Association study
To evaluate the association between genes of the neuregulin
signaling pathway (EREG-AREG and NRG1) and suscepti-
bility to BD, we performed a case–control association study.
The general characteristics of the association study dataset
are shown in Table 3. The distribution of clinical symptoms
in the Iranian BD patients (e.g., 98.7 % with oral aphthosis,
62.3 % with genital aphthosis, 55.2 % with skin lesions, 59.
7 % with ocular lesions) is in line with what has been
observed for larger datasets [16], suggesting that this is a
representative group. Cases and controls were matched for
age-at-examination (mean AAE±SD of 39.1±11.0 years in
BD and 40.0±12.3 years in controls, P=1.93E-01).
Since no SNPs in the EREG-AREG locus showed evi-
dence of association in the two published BD GWAS (per-
sonal communications by Dr. Elaine Remmers and Dr.
Nobuhisa Mizuki), we followed a haplotype tagging SNP
approach in order to explore the association of this locus
with BD. In an extended region of chromosome 8 (chr. 8:
31517663–32713793 bp), including NRG1, 17 and 22 SNPs
have been associated with BD in the Japanese and Turkish
populations (P<0.05), respectively (personal communica-
tions by Dr. Elaine Remmers and Dr. Nobuhisa Mizuki).
Since NRG1 is a very large gene spanning over 1.1 Mb, we
focused on 15 independent SNPs located within the smaller
region showing stronger evidence of association (chr. 8:
31517663–32066776 bp). In the EREG-AREG region, one
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SNP failed genotyping (rs2132065) and was not included in
the analysis. All the remaining SNPs were successfully
genotyped (Supplementary Table 4), and the association
results are shown in Supplementary Table 5.
In theEREG-AREG locus, we found an allelic association at
rs6845297 (P=2.51E-02, ORA [95%CI]=0.86 [0.75–0.98]),
located downstream of EREG. In NRG1, three markers dem-
onstrated an association with BD risk in the allelic test:
rs4489285 (P=2.01E-02, ORG [95%CI]=0.85 [0.73–0.97])
located upstream NRG1, and rs383632 (P=2.78E-02, ORT
[95%CI]=1.22 [1.02–1.46]) and rs1462891 (P=3.92E-02,
ORT [95 % CI]=1.18 [1.01–1.37]) located in NRG1.
rs4489285 was also associated with BD in a Japanese sample,
and rs383632 and rs1462891 were associated with BD in a
Turkish dataset (personal communications by Dr. Elaine
Remmers and Dr. Nobuhisa Mizuki). Since male to female
Table 1 Characterization of the sample used in the gene profiling study
ID Affection status Sex AAE (years) AAD (years) Major clinical symptoms IS
1 Case F 29 21 Oral and genital aphtosis, pseudofolliculitis Yes
2 Case F 40 35 Oral and genital aphtosis, pseudofolliculitis,
erythema nodosum, large vein thrombosis
Yes
3 Case F 36 35 Oral and genital aphtosis, pseudofolliculitis,
positive pathergy
No
4 Case F 29 21 Oral and genital aphtosis No
5 Case F 55 32 Oral and genital aphtosis, erythema nodosum,
positive pathergy
No
6 Case F 30 29 Oral and genital aphtosis, erythema nodosum,
positive pathergy
Yes
7 Case F 44 30 Oral and genital aphtosis, pseudofolliculitis
and posterior uveitis
Yes
8 Case F 46 44 Oral and genital aphtosis, pseudofolliculitis,
erythema nodosum, large vein thrombosis
No
9 Case M 20 17 Oral and genital aphtosis, pseudofolliculitis Yes
10 Case M 57 36 Oral aphtosis, pseudofolliculitis, erythema
nodosum, posterior uveitis
No
11 Case M 50 30 Oral and genital aphtosis, erythema nodosum,
large vein thrombosis
Yes
12 Case M 30 30 Oral aphtosis, pseudofolliculitis, erythema nodosum,
large vein thrombosis, positive pathergy
Yes
13 Case M 33 21 Oral, genital and skin aphtosis, pseudofolliculitis,
erythema nodosum, anterior and posterior uveitis
Yes
14 Case M 29 27 Oral and genital aphtosis, pseudofolliculitis No
15 Case M 28 24 Oral and genital aphtosis, erythema nodosum,
anterior and posterior uveitis, retinal vasculitis
Yes
Mean±SD 37.1±11.0 28.8±7.2
16 Control F 27 – – No
17 Control F 32 – – No
18 Control F 62 – – No
19 Control F 51 – – No
20 Control F 26 – – No
21 Control F 26 – – No
22 Control F 46 – – No
23 Control M 35 – – No
24 Control M 42 – – No
25 Control M 31 – – No
26 Control M 28 – – No
27 Control M 61 – – No
28 Control M 26 – – No
29 Control M 21 – – No
Mean±SD 36.7±13.5 –
The principal demographic and clinical characteristics of the study subjects are indicated, including the age-at-examination (AAE) for the patients
and controls and the age-at-diagnosis (AAD) for the patients. Patients were considered immunosuppressed (IS) if medicated with azathioprine,
cyclosporine, deflazacort, or thalidomide at the time of blood sample collection
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ratio was significantly higher in the BD group than in the
control group (52.5 % and 41.5 %, respectively, P=3.76E-
06), we tested the association of these four SNPs adjusted for
gender. They remained significantly associated (P≤0.05), al-
beit less so due to the concurrent loss of power associated with
co-variate adjustment. None of these SNPs survive Bonferroni
multiple testing correction. Haplotype associations did not
provide additional insights over single marker associations
(data not shown).
Meta-analysis of associated SNPs in NRG1
A combined analysis of the three associated SNPs at NRG1
with data from two published GWAS [2, 3] reveals that the
G allele of rs4489285 confers protection to BD (P=2.10E-
03, ORG [95 % CI]=0.83 [0.74–0.93]) and that the T alleles
of rs383632 (P=6.61E-04, ORT [95 % CI]=1.23 [1.09–1.
38]) and rs1462891 (P=7.88E-04, ORT[95 % CI]=1.19[1.
07–1.32]) confer risk to BD (Table 4). The association
consistency of these NRG1 polymorphisms is reinforced
by this meta-analysis and further supports their role in BD
susceptibility.
Epistatic interaction
Given that BD has clearly a multigenic inheritance and that
EREG, AREG, and NRG1 belong to the same cellular path-
way, we tested for the existence of non-additive gene–gene
interactions using the multifactor-dimensionality reduction
method. Supplementary Table 6 summarizes the best inter-
action models among all possible 2-, 3-, and 4-marker
models tested. The best 4-marker interaction model was a
significant predictor of Behçet's disease. The interaction
between rs6845297 and rs9992496 (both located down-
stream of EREG) and rs2345991 and rs956203 (located in
NRG1) had a statistically significant testing balanced accu-
racy of 0.566 (thus correctly classifying 56.6 % of the
individuals tested), and a cross-validation consistency of
5/10, indicating that the model was selected five times out
of ten cross-validation subsets (P=8.00E-03 after 1,000
permutations). The interaction dendogram depicted in
Fig. 2 shows a strong non-linear (epistatic) synergistic inter-
action between rs2345991 and rs956203 (located in NRG1)
with rs9992496 (located downstream of EREG). The dot-dash
line indicates an independent effect of rs6845297 (located
downstream of EREG) over the three other SNPs. These
results suggest that BD susceptibility can be modulated
by epistatic interactions between epidermal growth factor
receptor genes.
Discussion
Using a genomic and genetic convergence strategy for the
first time in the BD genetics field, the neuregulin signaling
pathway emerged as a novel player. Several genes in this
pathway (EREG, AREG, NRG1) were under-expressed in
BD cases when compared to controls, and genetic markers
in these loci were associated with BD susceptibility.
To the best of our knowledge, we performed the first
genome-wide study comparing the expression profiles of
BD patients and controls. PBMCs were considered a
relevant tissue for expression profiling since BD is a
generalized vasculitis characterized by a profound inflam-
matory and immune dysregulation [1]. Furthermore, given
that BD is a complex disease with multiple genes and
environmental factors implicated in its etiology, we did
not expect to find genes with major expression differ-
ences. Instead, the cumulative effect of small changes in
expression levels of a large number of genes, over time,
will result in the phenotype. Supporting this notion is the
finding that HLA-DQA1, a well-established locus for BD,
demonstrated a moderate differential expression in our
study (1.56-fold-change, P=3.19E-02). Therefore, we se-
lected genes to follow up based on a conservative thresh-
old of 1.20-fold-change.
Fig. 1 Illustration of the expression pattern differences among BD
cases and controls. Hierarchical clustering analysis of the 29 samples
using the 621 probe sets differentially expressed between BD cases and
controls, with a threshold of a 1.2-fold-change and P≤0.05. Each
column represents an individual, and each row a probe set. Higher
expression levels are dark red and lower levels are dark blue. Refer to
Table 1 for sample identification. This figure is produced with the
Partek software
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Pathway analysis of differentially expressed genes drew our
attention to the neuregulin signaling pathway and to some of its
constituents, in particular to EREG, AREG, and NRG1, which
were among the most under-expressed genes in BD patients.
Association studies of these genes revealed one polymorphism
in the EREG-AREG locus (rs6845297) and three SNPs in
NRG1 (rs4489285, rs383632, and rs1462891) associated with
BD. While the association of rs6845297 with BD has not been
previously tested, meta-analyses of our associations in NRG1
with those from previous reports in Turkish and Japanese [2, 3]
indicate that the susceptibility conferred by these variants is not
restricted to the Iranian population and strengthen the role of
NRG1 in BD susceptibility. The effect size of these NRG1
variants in BD susceptibility (ORs for the risk alleles of ap-
proximately 1.20) is much smaller than the effect of the well-
established HLA-B51 allele (OR of approximately 3.50) [2, 3]
but is of the same magnitude as reported non-HLA allelic
associations (ORs typically between 1.20 and 1.60) in
genome-wide associations studies for BD [2, 3, 17, 18]. More-
over, these three genetic markers have minor allele frequencies
ranging from 0.122 to 0.473 in HapMap Caucasian (CEU) and
Asian (CHB and JPT) populations, suggesting that these
common variants may influence risk for BD in a substantial
proportion of the population.
Concerns with multiple testing arise when screening
a large number of genes or genetic variants. The results
of the gene expression profiling were assessed for false
discovery rate using the Q value, but no correction for
the number of SNPs tested was performed. However,
the NRG1 meta-analyses and the observed epistatic
Table 2 Top genes differentially expressed between BD cases and controls
Probe set ID Gene Symbol Gene name P Fold-change
204419_x_at HBG /HBG2 Hemoglobin, gamma A/ hemoglobin, gamma G 1.35E-02 2.53
206108_s_at SRSF6 Serine/arginine-rich splicing factor 6 3.96E-02 2.45
208450_at LGALS2 Lectin, galactoside-binding, soluble, 2 1.11E-02 2.20
203961_at NEBL Nebulette 2.59E-02 2.10
234964_at TRD@ T cell receptor delta locus 1.91E-02 1.81
222027_at NUCKS1 Nuclear casein kinase and cyclin-dependent kinase substrate 1 3.06E-02 1.68
224009_x_at DHRS9 Dehydrogenase/reductase (SDR family) member 9 4.92E-03 1.60
209642_at BUB1 Budding uninhibited by benzimidazoles 1 homolog 4.54E-02 1.59
212671_s_at HLA-DQA1/2 Major histocompatibility complex, class II, DQ alpha 1/alpha 2 3.19E-02 1.57
216733_s_at GATM Glycine amidinotransferase 8.85E-03 1.55
221530_s_at BHLHE41 Basic helix-loop-helix family, member e41 4.08E-03 1.53
223751_x_at TLR10 Toll-like receptor 10 2.58E-03 1.51
228285_at TDRD9 Tudor domain containing 9 4.74E-02 −1.52
207314_x_at KIR3DL1/2 /LOC727787 Killer cell immunoglobulin-like receptor, three domains, long
cytoplasmic tail 1/2 /tail, 2-like
2.45E-02 −1.53
219359_at ATHL1 ATH1, acid trehalase-like 1 2.40E-02 −1.53
204908_s_at BCL3 B-cell CLL/lymphoma 3 1.24E-02 −1.53
216905_s_at ST14 Suppression of tumorigenicity 14 3.77E-03 −1.55
227510_x_at MALAT1 Metastasis associated lung adenocarcinoma transcript 1 1.12E-02 −1.57
204036_at LPAR1 Lysophosphatidic acid receptor 1 3.45E-02 −1.57
202464_s_at PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 2.35E-03 −1.58
213986_s_at C19orf6 Chromosome 19 open reading frame 6 5.46E-03 −1.62
1569599_at SAMSN1 SAM domain, SH3 domain and nuclear localization signals 1 3.84E-02 −1.63
209264_s_at TSPAN4 Tetraspanin 4 1.30E-02 −1.65
236244_at HNRNPU Heterogeneous nuclear ribonucleoprotein U 2.42E-02 −1.67
232530_at PLD1 Phospholipase D1, phosphatidylcholine-specific 1.06E-02 −1.72
206343_s_at NRG1 Neuregulin 1 3.12E-02 −1.76
205239_at AREG Amphiregulin 4.90E-02 −1.80
243296_at NAMPT Nicotinamide phosphoribosyltransferase 5.24E-04 −1.86
209686_at S100B S100 calcium binding protein B 7.92E-03 −2.25
205767_at EREG Epiregulin 2.99E-02 −2.39
The 30 genes with higher absolute value of fold-change difference between cases and controls are shown in this table. Genes with more than one
probe differentially expressed are represented by the probe with the higher fold-change difference between cases and controls
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interactions between genetic markers in NRG1 and
EREG-AREG reinforce the role of this pathway in BD
pathogenesis and warrant further validation in indepen-
dent population samples.
To date, these four genetic markers have not been asso-
ciated with other diseases (NHGRI catalogue of GWAS),
and no functions have been linked to these variants. How-
ever, NRG1 is encoded by 21 alternatively spliced exons
spanning more than 1.1 Mb which, through alternative
promoter usage and splicing, produce a variety of isoforms
with different affinities to their receptors [19]. Interestingly,
rs4489285 is in complete LD with rs1476540 (r2=1, CEU
population) that is located in a conserved transcription factor
binding site for GATA-1, GATA-2, and GATA-3 in humans,
and rs383632 is in complete LD with rs967205 (r2=1, CEU
population) which localizes to a conserved transcription
factor binding site for FOXO3a, FOXO3b, and FOXD1 in
humans (http://snp-nexus.org). The associated SNPs may
therefore work as proxies for variants in intronic enhancers.
Epiregulin, the most under-expressed gene in BD patients,
plays an essential role in immune/inflammatory-related re-
sponses in keratinocytes and macrophages in the epidermal
layer [20] and has a pivotal role in peptidoglycan-induced
proinflammatory cytokine production by antigen presenting
cells [21]. Indeed, deficiency of epiregulin in mice results in
chronic dermatitis and is correlated with an enhanced expres-
sion of the pro-inflammatory cytokine IL-18 by keratinocytes,
supporting the role of this molecule in inflammatory diseases.
An in silico analysis of the functional relevance of rs6845297
(located downstream of EREG) using SNPnexus (http://
snp-nexus.org/) did not reveal previous associations of
this polymorphism with other phenotypes or potential
effects on regulatory elements or conserved sequences.
Amphiregulin binds exclusively to ErbB1 [22], and its
overexpression has been associated with several autoim-
mune disorders such as systemic lupus erythematosus, pso-
riasis, and rheumatoid arthritis, and to synovial membrane
inflammation [23–25]. Studies in transgenic mice demon-
strate that amphiregulin overexpression in both the epider-
mis basal and suprabasal layer leads to a severe psoriasis-
like phenotype and skin inflammation with a rich dermal
and epidermal infiltration of neutrophils and lymphocytes
[26]. Epidermal AREG expression is a possible mediator of
innate cutaneous immunity and epidermal proliferation and
a potential trigger of both cutaneous psoriasis and psoriatic
arthritis [26].
Table 3 Principal demographic
and clinical characteristics of the
Iranian case–control sample
used in the association study
Characteristic Controls BD cases
N 839 976
Gender (n/N, % males) 348/839 (41.5) 512/976 (52.5)
Mean age-at-examination (years)±SD 40.0±12.3 39.1±11.0
Mean age-at-diagnosis (years)±SD – 32.2±9.2
Oral aphthosis (n/N, %) 0/839 (0) 963/976 (98.7)
Genital aphthosis (n/N, %) 0/839 (0) 608/976 (62.3)
Skin lesions (n/N, %) – 539/976 (55.2)
Pseudofolliculitis (n/N, %) – 409/539 (75.9)
Erythema nodosum (n/N, %) – 211/539 (39.1)
Skin aphthosis (n/N, %) – 30/539 (5.6)
Ophthalmologic manifestations (n/N, %) – 583/976 (59.7)
Anterior uveitis (n/N, %) – 420/583 (72.0)
Posterior uveitis (n/N, %) – 495/583 (84.9)
Retinal vasculitis (n/N, %) – 343/583 (58.8)
Joint manifestations (n/N, %) – 301/976 (30.8)
Arthralgia (n/N, %) – 139/301 (46.2)
Arthritis (n/N, %) – 188/301 (62.5)
Ankylosing spondylitis (n/N, %) – 18/301 (6.0)
Neurological manifestations (n/N, %) – 62/976 (6.4)
Vascular involvement (n/N, %) – 51/976 (5.2)
Gastro-intestinal manifestations (n/N, %) – 39/976 (4.0)
Epididymitis (n/N, %) – 22/512 (4.3)
Cardiac involvement (n/N, %) – 6/976 (0.6)
Pleuro-pulmonary involvement (n/N, %) – 6/976 (0.6)
Pathergy phenomenon (n/N, %) – 441/960 (45.9)
Family history of BD (n/N, %) – 86/936 (9.2)
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Because of its multiple isoforms and various func-
tional roles, NRG1 has been implicated in the patho-
physiology of numerous disorders, including breast
cancer, schizophrenia, and bipolar disorder in human
studies, atherosclerosis, myocardial dysfunction, and
multiple sclerosis in animal models [27]. Interestingly,
a schizophrenia-associated missense mutation in NRG1
has been associated with immune system deregulation
[27], establishing a link between this gene and immu-
nological disorders. NRG1 can bind either to ErbB3
(that has no active kinase domain) and/or ErbB4. ErbB4, as
well as two other genes of further downstream in the
pathway (DCN, SOS) (Supplementary Table 1), were dif-
ferentially expressed but not among the top genes, and
thus were not selected for follow-up in the association
study. On the other hand, ErbB1 was not differentially
expressed, suggesting that the intracellular signaling path-
way affected in BD may be via ErbB4 and not ErbB1. To
further establish the role of this pathway in BD pathogen-
esis, comprehensive immunogenetic/cellular studies may be
conducted.
We cannot formally exclude the possibility that the relatively
small number of samples and the different immunossupressants
(IS) taken by some patients had an impact on our findings in the
expression study, and may prevented the detection of
some important BD genes. Nevertheless, to minimize
the effect of this potential confounding factor, we includ-
ed the immunosuppression status as a co-variate in the
analysis. The rationale behind including immunosuppressed
patients in the expression profiling was that they are
expected to be in a physiological state that more closely
resembles the inactive phase of BD patients not taking
immunosuppressants drugs. Our group of cases is there-
fore thought to be more homogeneous than a group of
patients with varying degrees of disease activity. Fur-
thermore, current treatments for BD target mostly envi-
ronmental triggers (e.g., antibiotics to treat bacterial
infections) or self-amplifying disease mechanisms (e.g.,
immunosuppressants to block auto-immunity, NSAIDs
and corticosteroids to reduce inflammation), but are
not specific for this disorder and are unlikely to affect
the unique initial etiopathogenic mechanism(s) that we
are searching for. Also, unlike canonical pathways related to
immunity and inflammation, the neuroregulin signaling path-
way is not as likely to be influenced by immunomodulatory
drugs.
In summary, we have shown the power of combining
genome-wide expression studies with in silico pathways
Table 4 Association results of three SNPs in NRG1 in the Iranian dataset, in the discovery GWAS samples, and in the overall meta-analyses
SNP Gene Allele Dataset N Frequency P OR [95 % CI]
Cases Controls Cases Controls
rs4489285 NRG1 G Iranian 976 839 0.302 0.339 2.01E-02 0.85 [0.73–0.97]
Japanese [Ref. 3] 611 737 0.123 0.151 4.32E-02 0.79 [0.63–0.99]
Overall 2.10E-03 0.83 [0.74–0.93]
rs383632 NRG1 T Iranian 976 839 0.180 0.153 2.78E-02 1.22 [1.02–1.46]
Turkish [Ref. 2] 1211 1270 0.166 0.140 9.16E-03 1.23 [1.05–1.43]
Overall 6.61E-04 1.23 [1.09–1.38]
rs1462891 NRG1 T Iranian 976 839 0.261 0.231 3.92E-02 1.18 [1.01–1.37]
Turkish [Ref. 2] 1215 1278 0.236 0.205 7.86E-03 1.20 [1.05–1.37]
Overall 7.88E-04 1.19 [1.07–1.32]
At each marker, the OR and CI refer to the allele on the forward strand of the human genome reference sequence. Significant P values are bolded
Fig. 2 Interaction dendrogram
for the EREG-AREG and NRG1
polymorphisms in BD
susceptibility. The length of the
dendrogram branch that
connects two polymorphisms
indicates the strength of
interaction (the shorter the
branch, the stronger is the
interaction)
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analysis and association studies in the identification of
novel genetic risk factors for BD. We have also yielded
a series of candidate genes, blood biomarkers, pathways,
and mechanisms that are prime targets for follow-up in
hypothesis driven studies. Future research towards un-
derstanding the role of these genes and pathways in BD
pathogenesis include candidate gene association studies,
deep re-sequencing of selected genes, biochemical, cellular,
and animal work.
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